Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$216.00K$216.00K−85.1% vs Q1 2021 Net Income-$25.69M-$25.69MN/M vs Q1 2021 EPS Diluted-$0.98-$0.98N/M vs Q1 2021 Operating Income-$25,889,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
Free Cash Flowderived-$21,221,000N/M Margins · derivedOperating margin-11985.6%−10709.6 pt vs Q1 2021
Net margin-11894.9%−10622.7 pt vs Q1 2021
ended Mar 31, 2022 · filed May 13, 2022 · 43 d after period end